
Docebo (DCBO) Stock Forecast & Price Target
Docebo (DCBO) Analyst Ratings
Bulls say
Docebo is viewed positively because it is consistently outgrowing a difficult L&D spending backdrop while taking enterprise share from incumbents, with 3Q26 revenue of $70.3mm rising 14.1% Y/Y and ARR reaching $261.5mm, up 11.0% Y/Y, or 13.4% excluding OEM, acquired ARR and FX effects. Its fundamentals are further strengthened by expanding customer quality, including 609 customers above $100k in ARR, a 24% Y/Y increase in consolidated ACV to $77.9k, and solid profitability with $16.7mm of adjusted EBITDA in 3Q26 and a 20.2% FY26 margin outlook. Management’s willingness to invest in healthcare and life sciences, plus channel expansion and new enterprise wins, supports a long runway for durable growth and margin expansion while still maintaining a balanced leverage profile after the $60mm special dividend.
Bears say
Docebo is viewed negatively because the bear case assumes it cannot efficiently cross-sell or upsell incremental modules to its existing customer base, limiting monetization of its platform and compressing growth opportunities. It also may fail to generate meaningful returns from international expansion, which would leave revenue growth below 10% and suggest the business is struggling to scale beyond its core North American customer base. Together, these assumptions point to weak operating leverage, limited expansion of average revenue per customer, and a valuation risk tied to slowing top-line momentum.
This aggregate rating is based on analysts' research of Docebo and is not a guaranteed prediction by Public.com or investment advice.
Docebo (DCBO) Analyst Forecast & Price Prediction
Start investing in Docebo (DCBO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Docebo (DCBO) Forecast
Docebo (DCBO) Analyst Forecast & Price Prediction
Start investing in Docebo (DCBO)
Order type
Buy in
Order amount
Est. shares
0 shares